Research programme: human papillomavirus vaccines - RedbiotecAlternative Names: RBT 201; RBT 202
Latest Information Update: 19 Jan 2012
At a glance
- Originator Redbiotec
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Human papillomavirus infections
Most Recent Events
- 17 Jan 2012 This programme is still in active development
- 07 Oct 2008 Preclinical trials in Human papillomavirus infections in Switzerland (Parenteral)